768 related articles for article (PubMed ID: 29904917)
1. Lumichrome inhibits osteoclastogenesis and bone resorption through suppressing RANKL-induced NFAT activation and calcium signaling.
Liu C; Cao Z; Zhang W; Tickner J; Qiu H; Wang C; Chen K; Wang Z; Tan R; Dong S; Xu J
J Cell Physiol; 2018 Nov; 233(11):8971-8983. PubMed ID: 29904917
[TBL] [Abstract][Full Text] [Related]
2. Modulating calcium-mediated NFATc1 and mitogen-activated protein kinase deactivation underlies the inhibitory effects of kavain on osteoclastogenesis and bone resorption.
Guo Q; Cao Z; Wu B; Chen F; Tickner J; Wang Z; Qiu H; Wang C; Chen K; Tan R; Gao Q; Xu J
J Cell Physiol; 2018 Jan; 234(1):789-801. PubMed ID: 30078210
[TBL] [Abstract][Full Text] [Related]
3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
4. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
[TBL] [Abstract][Full Text] [Related]
5. Daidzin inhibits RANKL-induced osteoclastogenesis in vitro and prevents LPS-induced bone loss in vivo.
Wei G; Liang T; Wei C; Nong X; Lu Q; Zhao J
J Cell Biochem; 2019 Apr; 120(4):5304-5314. PubMed ID: 30378146
[TBL] [Abstract][Full Text] [Related]
6. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
[TBL] [Abstract][Full Text] [Related]
7. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
8. Ginsenoside Rb2 inhibits osteoclast differentiation through nuclear factor-kappaB and signal transducer and activator of transcription protein 3 signaling pathway.
Cong F; Liu J; Wang C; Yuan Z; Bi L; Liang J; Su K; Qiu Y; Song T; Fan J; Chao G
Biomed Pharmacother; 2017 Aug; 92():927-934. PubMed ID: 28605877
[TBL] [Abstract][Full Text] [Related]
9. Macrolactin F inhibits RANKL-mediated osteoclastogenesis by suppressing Akt, MAPK and NFATc1 pathways and promotes osteoblastogenesis through a BMP-2/smad/Akt/Runx2 signaling pathway.
Li L; Sapkota M; Gao M; Choi H; Soh Y
Eur J Pharmacol; 2017 Nov; 815():202-209. PubMed ID: 28919027
[TBL] [Abstract][Full Text] [Related]
10. Neferine suppresses osteoclast differentiation through suppressing NF-κB signal pathway but not MAPKs and promote osteogenesis.
Chen S; Chu B; Chen Y; Cheng X; Guo D; Chen L; Wang J; Li Z; Hong Z; Hong D
J Cell Physiol; 2019 Dec; 234(12):22960-22971. PubMed ID: 31127627
[TBL] [Abstract][Full Text] [Related]
11. Neohesperidin suppresses osteoclast differentiation, bone resorption and ovariectomised-induced osteoporosis in mice.
Tan Z; Cheng J; Liu Q; Zhou L; Kenny J; Wang T; Lin X; Yuan J; Quinn JMW; Tickner J; Hong G; Qin A; Zhao J; Xu J
Mol Cell Endocrinol; 2017 Jan; 439():369-378. PubMed ID: 27664516
[TBL] [Abstract][Full Text] [Related]
12. Cajaninstilbene acid inhibits osteoporosis through suppressing osteoclast formation and RANKL-induced signaling pathways.
Sun Y; Liu Y; He W; Wang C; Tickner J; Kuek V; Zhou C; Wang H; Zou X; Hong Z; Yang F; Shao M; Chen L; Xu J
J Cell Physiol; 2019 Jul; 234(7):11792-11804. PubMed ID: 30515822
[TBL] [Abstract][Full Text] [Related]
13. (-)-Epigallocatechin-3-gallate inhibits RANKL-induced osteoclastogenesis via downregulation of NFATc1 and suppression of HO-1-HMGB1-RAGE pathway.
Nishioku T; Kubo T; Kamada T; Okamoto K; Tsukuba T; Uto T; Shoyama Y
Biomed Res; 2020; 41(6):269-277. PubMed ID: 33268671
[TBL] [Abstract][Full Text] [Related]
14. Specnuezhenide suppresses diabetes-induced bone loss by inhibiting RANKL-induced osteoclastogenesis.
Ye X; Jiang J; Yang J; Yan W; Jiang L; Chen Y
Acta Biochim Biophys Sin (Shanghai); 2022 Aug; 54(8):1080-1089. PubMed ID: 35929595
[TBL] [Abstract][Full Text] [Related]
15. Palmitoleic Acid Inhibits RANKL-Induced Osteoclastogenesis and Bone Resorption by Suppressing NF-κB and MAPK Signalling Pathways.
van Heerden B; Kasonga A; Kruger MC; Coetzee M
Nutrients; 2017 Apr; 9(5):. PubMed ID: 28452958
[TBL] [Abstract][Full Text] [Related]
16. Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation.
Chen D; Ye Z; Wang C; Wang Q; Wang H; Kuek V; Wang Z; Qiu H; Yuan J; Kenny J; Yang F; He J; Liu Y; Wang G; Zhang M; Zhang G; Wang J; Chen P; Xu J
Pharmacol Res; 2020 Sep; 159():104944. PubMed ID: 32454224
[TBL] [Abstract][Full Text] [Related]
17. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
18. Bergapten suppresses RANKL-induced osteoclastogenesis and ovariectomy-induced osteoporosis via suppression of NF-κB and JNK signaling pathways.
Chen G; Xu Q; Dai M; Liu X
Biochem Biophys Res Commun; 2019 Feb; 509(2):329-334. PubMed ID: 30579598
[TBL] [Abstract][Full Text] [Related]
19. Stattic inhibits RANKL-mediated osteoclastogenesis by suppressing activation of STAT3 and NF-κB pathways.
Li CH; Xu LL; Jian LL; Yu RH; Zhao JX; Sun L; Du GH; Liu XY
Int Immunopharmacol; 2018 May; 58():136-144. PubMed ID: 29587202
[TBL] [Abstract][Full Text] [Related]
20. A novel RANKL-targeted flavonoid glycoside prevents osteoporosis through inhibiting NFATc1 and reactive oxygen species.
Hong G; Chen Z; Han X; Zhou L; Pang F; Wu R; Shen Y; He X; Hong Z; Li Z; He W; Wei Q
Clin Transl Med; 2021 May; 11(5):e392. PubMed ID: 34047464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
